- Product
- Series of non-face-to-face medical care platforms close down
- by Jung, Sae-Im Jun 16, 2023 05:55am
- More than 30 platforms that were created while temporary non-face-to-face medical care was allowed, initiated self-restructuring. With the government starting a non-face-to-face medical care pilot project under the ‘only allowed for returning patient’ rule rather than allowing the first-time visits requested by the platforms, companies
- Company
- Ultomiris under review as myasthenia gravis Tx in Korea
- by Eo, Yun-Ho Jun 16, 2023 05:54am
- The paroxysmal nocturnal hemoglobinuria (PNH) treatment ‘Ultomiris’ is seeking to secure an indication for myasthenia gravis (gMC) in Korea. According to industry sources, AstraZeneca Korea submitted an application to the Ministry of Food and Drug Safety and is being reviewed for the indication to treat adults with generalized myastheni
- Opinion
- [Reporter's view] Homework left by ASCO 2023’ hot topic
- by Jung, Sae-Im Jun 16, 2023 05:53am
- There is one thing in common with the major studies that drew attention at this year's Annual Conference of the American Society of Clinical Oncology (ASCO 2023). It has achieved successful results in adjuvant therapy targeting early cancer where surgery is possible. New drugs used in terminal cancers, such as metastasis and recursation, have
- Policy
- Why Vyndamax and Tabrecta’s reimb were unable to pass DREC
- by Lee, Tak-Sun Jun 15, 2023 05:38am
- i1 The reasons why Vyndamax and Tabrecta, the two drugs that had high reimbursement demand, were unable to pass the Health Insurance Review and Assessment Service’s review were revealed. The two drugs were determined to be ineligible for reimbursement by HIRA’s Drug Reimbursement Evaluation Committee (DREC) at its meeting that was held in
- Company
- Development of Recomid generics fierce despite reeval issue
- by Kim, Jin-Gu Jun 15, 2023 05:38am
- Development of generics of Yuhan Corp’s antiulcer drug, ‘Recomid SR’ (rebamipide),’ continues to remain fierce in Korea. Despite the authorities’ notification of the reevaluation of rebamipide, generic companies are continuing to develop their generic versions as planned along with patent challenges. The rebamipide-based antiulcer
- Company
- Samsung Bioepis emphasized the role of a similar
- by Hwang, byoung-woo Jun 14, 2023 05:38am
- As financial savings and patient benefits, such as health insurance, are emerging as major issues both domestically and globally, biosimilars that have the same effect as the original and are cheaper are expanding their presence. It is the expert's view that the effects are felt even when looking at overseas cases where active prescriptions a
- Company
- The efficient use of CDK 4/6 needs to be discussed
- by Jun 14, 2023 05:38am
- CDK4/6 inhibitors, which were prevalent in metastatic breast cancer, have expanded their scope to early breast cancer. Following Lily Verzenio, Novartis Kisqali demonstrated the effect of adjuvant therapy after surgery through a clinical presentation this year. As the role of CDK4/6 inhibitors expands, new concerns are emerging to achieve the
- Company
- Hanmi to examine the possibility of the Poseltinib effect
- by Chon, Seung-Hyun Jun 14, 2023 05:38am
- Hanmi Pharm is examining the possibility of new indications with new drug candidates returned by multinational pharmaceutical company Eli Lilly. Hanmi Pharmaceutical announced on the 12th that it announced the interim results of phase 2 clinical trial of three-drug combination therapy, a follow-up study of the BTK inhibitor Poseltinib, at th
- Company
- Hanmi's NASH drug candidate, designated as a fast track
- by Jun 14, 2023 05:38am
- Hanmi Pharmaceutical announced on the 13th that Efinopegdutide, a new drug candidate for non-alcoholic steatohepatitis (NASH), has been designated as fast-track by the US Food and Drug Administration (FDA). Efinopegdutide is a dual agonist that simultaneously activates the GLP-1 receptor, which helps the secretion of insulin and suppresses ap
- Company
- Will a new treatment option be introduced for gastric cancer
- by Jung, Sae-Im Jun 14, 2023 05:38am
- Unlike lung cancer and breast cancer, gastric cancer has been regarded as one type of cancer that has not benefited from the development of new anticancer drugs. For the past decade, chemotherapy has been the standard first-line treatment for patients with HER2 gene-negative metastatic gastric cancer. This means that there were no suitable
